Abstract
Background
Polycystic ovarian syndrome (PCOS) is the most prevalent metabolic disorder in reproductive-age women. It is indeed a multifactorial condition evidenced by ovarian dysfunction, hyperandrogenaemia, infertility, hormonal imbalance and chronic anovulation. Experimental evidence infers that PCOS women are prone to cardiovascular problems and insulin resistance.
Purpose
To furnish the details about the association of inflammatory markers in PCOS.
Design
An extensive literature search on PubMed, science direct and google scholar has been performed for articles about PCOS and inflammation in PCOS. A comprehensive analysis using original articles, reviews, systemic and meta-analysis was conducted for better understanding the relationship between inflammatory cytokines and PCOS.
Results
The inflammatory markers perform a substantial part in managing the functions of the ovary. Any disturbances in their levels can lead to ovarian dysfunction. Inflammatory markers are associated with PCOS pathogenesis. The interplay between inflammatory cytokines in the PCOS ovary strongly implies that inflammation is one of the most potent risk factors of PCOS.
Conclusion
Inflammatory markers have a significant role in regulating the ovary. This manuscript highlights the significance of metabolic and inflammatory markers with PCOS. Since PCOS is always considered as a metabolic disorder, researchers can also consider focusing on the relationship between the inflammatory markers in PCOS to establish a new treatment or management of the disease and to improve women's health.
Similar content being viewed by others
References
Buvinic M, Médici A, Fernández E, Torres AC (2006) Gender differentials in health. Dis Control Prior Dev Ctries 2:195–210
Jia G, Tao H, Xue Y et al (2018) Analysis of secreted peptidome from omental adipose tissue in polycystic ovarian syndrome patients. J Cell Physiol 233:5885–5894
Louwers YV, Laven JSE (2020) The polycystic ovary syndrome (PCOS) BT—female reproductive dysfunction. In: Fauser BCJM (ed) Petraglia F. Springer International Publishing, Champaign, pp 1–23
Vidya Bharathi R, Swetha S, Neerajaa J et al (2017) An epidemiological survey: effect of predisposing factors for PCOS in Indian urban and rural population. Middle East Fertil Soc J 22:313–316. https://doi.org/10.1016/j.mefs.2017.05.007
Brady C, Mousa SS, Mousa SA (2009) Polycystic ovary syndrome and its impact on women’s quality of life: more than just an endocrine disorder. Drug Healthc Patient Saf 1:9
Christakou CD, Diamanti-Kandarakis E (2008) Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome. Women’s Heal 4:583–594
Hatziagelaki E, Pergialiotis V, Kannenberg JM et al (2019) Association between biomarkers of low-grade inflammation and sex hormones in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. https://doi.org/10.1055/a-0992-9114
Azziz R, Carmina E, Chen Z et al (2016) Polycystic ovary syndrome. Nat rev Dis Prim 2:16057. https://doi.org/10.1038/nrdp.2016.57
Teede HJ, Misso ML, Costello MF et al (2018) Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 33:1602–1618
Hung J-H, Hu L-Y, Tsai S-J et al (2014) Risk of psychiatric disorders following polycystic ovary syndrome: a nationwide population-based cohort study. PLoS ONE 9:e97041
Navaratnarajah R, Pillay OC, Hardiman P (2008) Polycystic ovary syndrome and endometrial cancer. Seminars in reproductive medicine. Thieme Medical Publishers, New York, pp 62–71
Mulders AG, Laven JSE, Eijkemans MJC et al (2004) Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum Reprod 19:2036–2042
Stein IF (1935) Amenorrhea associated with bilateral polycystic ovaries. Am J Obs Gynecol 29:181–191
Fauser BCJM, Tarlatzis F et al (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod 19:41–47. https://doi.org/10.1093/humrep/deh098
Legro RS, Arslanian SA, Ehrmann DA et al (2013) Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 98:4565–4592
Azziz R, Carmina E, Dewailly D et al (2006) Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 91:4237–4245. https://doi.org/10.1210/jc.2006-0178
Moran L, Teede H (2009) Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 15:477–488
De Leo V, Musacchio MC, Cappelli V et al (2016) Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol 14:1–17. https://doi.org/10.1186/s12958-016-0173-x
Tan S, Hahn S, Benson S et al (2008) Psychological implications of infertility in women with polycystic ovary syndrome. Hum Reprod 23:2064–2071
Reddy KR, Deepika MLN, Ishaq M, Jahan P (2011) Haptoglobin a pleiotropic marker in polycystic ovary syndrome a study from south india. Am J Biochem Mol Biol 1:399–404
Ranjith Reddy K, Deepika MLN, Latha KP, Sangurthi SR (2015) Polycystic ovary syndrome: role of aromatase gene variants in south Indian women. Int J Pharm Bio Sci 6:1283–1296
Zehra B, Khursheed AA (2018) Polycystic ovarian syndrome: symptoms, treatment and diagnosis: a review. J Pharmacogn Phytochem 7:875–880
Nisenblat V, Norman RJ (2009) Androgens and polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes 16:224–231
Van Santbrink EJ, Hop WC, Fauser BCJM (1997) Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome. Fertil Steril 67:452–458
Fauser BC, Pache TD, Lamberts SW et al (1991) Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease. J Clin Endocrinol Metab 73:811–817. https://doi.org/10.1210/jcem-73-4-811
Abbott DH, Barnett DK, Bruns CM, Dumesic DA (2005) Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum Reprod Update 11:357–374
Diamanti-Kandarakis E, Dunaif A (2012) Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33:981–1030
Dumesic DA, Oberfield SE, Stener-Victorin E et al (2015) Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev 36:487–525
Pauli JM, Raja-Khan N, Wu X, Legro RS (2011) Current perspectives of insulin resistance and polycystic ovary syndrome. Diabet Med 28:1445–1454
Nestler JE, Jakubowicz DJ, Falcon de Vargas A et al (1998) Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 83:2001–2005
Adashi ELIY, Hsueh AJW, Yen SSC (1981) Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology 108:1441–1449
Alesci S, Koch CA, Bornstein SR, Pacak K (2001) Adrenal androgens regulation and adrenopause. Endocr Regul 35:95–100
Wallace IR, McKinley MC, Bell PM, Hunter SJ (2013) Sex hormone binding globulin and insulin resistance. Clin Endocrinol 78:321–329
Selva DM, Hogeveen KN, Innis SM, Hammond GL (2007) Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J Clin Invest 117:3979–3987
Mounier C, Dumas V, Posner BI (2006) Regulation of hepatic insulin-like growth factor-binding protein-1 gene expression by insulin: central role for mammalian target of rapamycin independent of forkhead box O proteins. Endocrinology 147:2383–2391
van der Spuy ZM, Dyer SJ (2004) The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 18:755–771
Jamnongjit M, Hammes SR (2006) Ovarian steroids: the good, the bad, and the signals that raise them. Cell Cycle 5:1178–1183
Cassar S, Misso ML, Hopkins WG et al (2016) Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies. Hum Reprod 31:2619–2631
Torchen LC (2017) Cardiometabolic risk in PCOS: more than a reproductive disorder. Curr Diab Rep. https://doi.org/10.1007/s11892-017-0956-2
Randeva HS, Tan BK, Weickert MO et al (2012) Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 33:812–841. https://doi.org/10.1210/er.2012-1003
Escobar-Morreale HF, San Millán JL (2007) Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 18:266–272
Pasquali R, Gambineri A, Pagotto U (2006) The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG An Int J Obstet Gynaecol 113:1148–1159
Sam S, Dunaif A (2003) Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 14:365–370
Stocco C (2012) Tissue physiology and pathology of aromatase. Steroids 77:27–35
Pasquali R, Casimirri F (1993) The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol (Oxf) 39:1–16
Sirotkin AV (2011) Cytokines: signalling molecules controlling ovarian functions. Int J Biochem Cell Biol 43:857–861
Qiao J, Feng HL (2011) Extra-and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum Reprod Update 17:17–33
Richards JS, Pangas SA (2010) The ovary: basic biology and clinical implications. J Clin Invest 120:963–972
BrännströmNorman MRJ (1993) Involvement of leukocytes and cytokines in the ovulatory process and corpus luteum function. Hum Reprod 8:1762–1775
Field SL, Dasgupta T, Cummings M, Orsi NM (2014) Cytokines in ovarian folliculogenesis, oocyte maturation and luteinisation. Mol Reprod Dev 81:284–314
Niu Z, Ye Y, Xia L et al (2017) Follicular fluid cytokine composition and oocyte quality of polycystic ovary syndrome patients with metabolic syndrome undergoing in vitro fertilization. Cytokine 91:180–186
Vgontzas AN, Bixler EO, Chrousos GP (2003) Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J Intern Med 254:32–44
Zhang C, Zhao Y, Li R et al (2014) Metabolic heterogeneity of follicular amino acids in polycystic ovary syndrome is affected by obesity and related to pregnancy outcome. BMC Pregnancy Childbirth 14:11
González F (2011) Inflammation in Polycystic Ovary Syndrome: Underpinning of insulin resistance and ovarian dysfunction. Steroids 77:300–305. https://doi.org/10.1016/j.steroids.2011.12.003
Osborn O, Olefsky JM (2012) The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 18:363–374. https://doi.org/10.1038/nm.2627
Vural P, Deǧirmencioǧlu S, Saral NY, Akgül C (2010) Tumor necrosis factor α (-308), interleukin-6 (-174) and interleukin-10 (-1082) gene polymorphisms in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 150:61–65. https://doi.org/10.1016/j.ejogrb.2010.02.010
Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411–452
Zolti M, Meirom R, Shemesh M et al (1990) Granulosa cells as a source and target organ for tumor necrosis factor-α. FEBS Lett 261:253–255
Veldhuis JD, Garmey JC, Urban RJ et al (1991) Ovarian actions of tumor necrosis factor-α (TNFα): pleiotropic effects of TNFα on differentiated functions of untransformed swine granulosa cells. Endocrinology 129:641–648
Wang LJ, Brännström M, Robertson SA, Norman RJ (1992) Tumor necrosis factor α in the human ovary: presence in follicular fluid and effects on cell proliferation and prostaglandin production. Fertil Steril 58:934–940
Roby KF, Terranova PF (1990) Effects of tumor necrosis factor-α in vitro on steroidogenesis of healthy and atretic follicles of the rat: theca as a target. Endocrinology 126:2711–2718
Emoto N, Baird A (1988) The effect of tumor necrosis factor/cachectin on follicle-stimulating hormone-induced aromatase activity in cultured rat granulosa cells. Biochem Biophys Res Commun 153:792–798
Brannstrom M, Bonello N, Wang LJ, Norman RJ (1995) Effects of tumour necrosis factor alpha (TNF alpha) on ovulation in the rat ovary. Reprod Fertil Dev 7:67–73
Andreani CL, Payne DW, Packman JN et al (1991) Cytokine-mediated regulation of ovarian function. Tumor necrosis factor alpha inhibits gonadotropin-supported ovarian androgen biosynthesis. J Biol Chem 266:6761–6766
Kaipia A, Chun S-Y, Eisenhauer K, Hsueh AJ (1996) Tumor necrosis factor-alpha and its second messenger, ceramide, stimulate apoptosis in cultured ovarian follicles. Endocrinology 137:4864–4870
Soboloff J, Sasaki H, Tsang BK (2001) Follicular stage-dependent tumor necrosis factor α-induced hen granulosa cell integrin production and survival in the presence of transforming growth factor α in vitro. Biol Reprod 65:477–487
Crespo D, Bonnet E, Roher N et al (2010) Cellular and molecular evidence for a role of tumor necrosis factor alpha in the ovulatory mechanism of trout. Reprod Biol Endocrinol 8:34
Szlosarek PW, Grimshaw MJ, Wilbanks GD et al (2007) Aberrant regulation of argininosuccinate synthetase by TNF-α in human epithelial ovarian cancer. Int J cancer 121:6–11
Sethi G, Sung B, Aggarwal BB (2008) TNF: a master switch for inflammation to cancer. Front Biosci 13:5094–5107
Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev cancer 9:361–371
Balkwill F (2006) TNF-α in promotion and progression of cancer. Cancer Metastasis Rev 25:409
Szlosarek PW, Grimshaw MJ, Kulbe H et al (2006) Expression and regulation of tumor necrosis factor α in normal and malignant ovarian epithelium. Mol Cancer Ther 5:382–390
Dobrzycka B, Terlikowski SJ, Garbowicz M et al (2009) Tumor necrosis factor-alpha and its receptors in epithelial ovarian cancer. Folia Histochem Cytobiol 47:609–613
Daraï E, Detchev R, Hugol D, Quang NT (2003) Serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. Hum Reprod 18:1681–1685
Hotamisligil GS, Budavari A, Murray D, Spiegelman BM (1994) Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 94:1543–1549
Stephens JM, Pekala PH (1991) Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol Chem 266:21839–21845
Rojas J, Chávez M, Olivar L et al (2014) Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int J Reprod Med. https://doi.org/10.1155/2014/719050
Figueroa F, Davicino R, Micalizzi B et al (2012) Macrophage secretions modulate the steroidogenesis of polycystic ovary in rats: effect of testosterone on macrophage pro-inflammatory cytokines. Life Sci 90:733–739
Thathapudi S, Kodati V, Erukkambattu J et al (2014) Tumor necrosis factor-alpha and polycystic ovarian syndrome: a clinical, biochemical, and molecular genetic study. Genet Test Mol Biomarkers 18:605–609
Gao L, Gu Y, Yin X (2016) High serum tumor necrosis factor-alpha levels in women with polycystic ovary syndrome: a meta-analysis. PLoS ONE 11:1–18. https://doi.org/10.1371/journal.pone.0164021
Amato G, Conte M, Mazziotti G et al (2003) Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol 101:1177–1182
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545
Nilsson MB, Langley RR, Fidler IJ (2005) Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 65:10794–10800. https://doi.org/10.1158/0008-5472.CAN-05-0623
Adashi EY (1990) The potential relevance of cytokines to ovarian physiology: the emerging role of resident ovarian cells of the white blood cell series. Endocr Rev 11:454–464. https://doi.org/10.1210/edrv-11-3-454
Łukaszewicz M, Mroczko B, Szmitkowski M (2007) Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease. Pol Arch Med Wewn 117:247–251. https://doi.org/10.20452/pamw.144
Sanguinete MMM, De OPH, Martins-Filho A et al (2017) Serum IL-6 and IL-8 correlate with prognostic factors in ovarian cancer. Immunol Invest 46:677–688. https://doi.org/10.1080/08820139.2017.1360342
Bersinger NA, Kollmann Z, Von Wolff M (2014) Serum but not follicular fluid cytokine levels are increased in stimulated versus natural cycle IVF: a multiplexed assay study. J Reprod Immunol 106:27–33
Díaz PU, Stangaferro ML, Gareis NC, Silvia WJ, Matiller V, Salvetti NR, Rey F, Barberis F, Cattaneo L, HHO (2015) Characterization of persistent follicles induced by prolonged treatment with progesterone in dairy cows: an experimental model for the study of ovarian follicular cysts. Theriogenology 84:1149–1160
Abramov Y, Schenker JG, Lewin A et al (1996) Endocrinology: plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum Reprod 11:1381–1386. https://doi.org/10.1093/oxfordjournals.humrep.a019404
Tarkun İ, Çetinarslan B, Türemen E et al (2006) Association between circulating tumor necrosis factor-alpha, interleukin-6, and insulin resistance in normal-weight women with polycystic ovary syndrome. Metab Syndr Relat Disord 4:122–128
González F, Sia CL, Stanczyk FZ et al (2012) Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome. Endocrine 42:726–735. https://doi.org/10.1007/s12020-012-9728-6
Samy N, Hashim M, Sayed M, Said M (2009) Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Dis Markers 26:163–170
Xie K (2001) Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12:375–391
Arici A, Oral E, Bukulmez O et al (1996) Interleukin-8 expression and modulation in human preovulatory follicles and ovarian cells. Endocrinology 137:3762–3769
Rizk B, Aboulghar M, Smitz J, Ron-El R (1997) The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 3:255–266
Chang RJ, Gougeon A, Erickson GF (1998) Evidence for a neutrophil–interleukin-8 system in human folliculogenesis. Am J Obstet Gynecol 178:650–657
Goto J, Suganuma N, Takata K et al (2002) Morphological analyses of interleukin-8 effects on rat ovarian follicles at ovulation and luteinization in vivo. Cytokine 20:168–173
Gazvani MR, Bates M, Vince G et al (2000) Follicular fluid concentrations of interleukin-12 and interleukin-8 in IVF cycles. Fertil Steril 74:953–958
Edgell T, Martin-Roussety G, Barker G et al (2010) Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol 136:1079–1088
Wang Y, Xu RC, Zhang XL et al (2012) Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine 59:145–155
Fasciani A, D’ambrogio Bocci GG et al (2000) High concentrations of the vascular endothelial growth factor and interleukin-8 in ovarian endometriomata. Mol Hum Reprod 6:50–54
Ene Nicolae CD, Nicolae I (2016) Interleukin 8 serum concentration, but not lactate dehydrogenase activity, positively correlates to CD34 antigen in melanoma tumors. J Immunoass Immunochem 37:463–471
Yoshimoto T, Yoshimoto T (2014) Cytokine Frontiers. Springer, Tokyo
Cordero MD, Alcocer-Gómez E (2018) Inflammasomes: clinical and therapeutic implications. Springer, Tokyo
Ali DES, Shah M, Ali A et al (2019) Treatment with metformin and combination of metformin plus pioglitazone on serum levels of IL-6 and IL-8 in polycystic ovary syndrome: a randomized clinical trial. Horm Metab Res 51:714–722. https://doi.org/10.1055/a-1018-9606
Moore KW, de Waal MR, Coffman RL, O’Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765
Fiorentino DF, Zlotnik A, Mosmann TR et al (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147:3815–3822
Hashii K, Fujiwara H, Yoshioka S et al (1998) Peripheral blood mononuclear cells stimulate progesterone production by luteal cells derived from pregnant and non-pregnant women: possible involvement of interleukin-4 and interleukin-10 in corpus luteum function and differentiation. Hum Reprod 13:2738–2744. https://doi.org/10.1093/humrep/13.10.2738
Scarpelli D, Cardellini M, Andreozzi F et al (2006) Variants of the interleukin-10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in Caucasian Italian subjects. Diabetes 55:1529–1533
Talaat RM, Mohamed YA, Mohamad EH et al (2016) Interleukin 10 (−1082 G/A) and (−819 C/T) gene polymorphisms in Egyptian women with polycystic ovary syndrome (PCOS). Meta Gene 9:254–258
Sylus A, Hanumanthappa N, Sridhar M et al (2018) Clomiphene Citrate Increases Nitric Oxide, Interleukin-10 and reduces matrix metalloproteinase-9 in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. https://doi.org/10.1016/j.ejogrb.2018.06.007
Karadeniz M, Erdogan M, Zengi A et al (2008) Polymorphism of the interleukin-10 gene in polycystic ovary syndrome. Int J Immunogenet 35:119–123. https://doi.org/10.1111/j.1744-313X.2007.00746.x
Lebel-Binay S, Berger A, Zinzindohoue F et al (2000) Interleukin-18: biological properties and clinical implications. Eur Cytokine Netw 11:15–26
Kohka H, Yoshino T, Iwagaki H et al (1998) Interleukin-18/interferon-γ-inducing factor, a novel cytokine, up-regulates ICAM-1 (CD54) expression in KG-1 cells. J Leukoc Biol 64:519–527
Dinarello CA (1999) IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 103:11–24
Barak V, Elchalal U, Edelstein M et al (2004) Interleukin-18 levels correlate with severe ovarian hyperstimulation syndrome. Fertil Steril 82:415–420. https://doi.org/10.1016/j.fertnstert.2004.03.024
Bornstein SR, Rutkowski H, Vrezas I (2004) Cytokines and steroidogenesis. Mol Cell Endocrinol 215:135–141
Tsuji Y, Adachi S, Koyama K et al (2001) Expression of interleukin-18 and its receptor in mouse ovary. Am J Reprod Immunol 46:349–357
Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12:53–72
Vidal-Vanaclocha F, Mendoza L, Telleria N et al (2006) Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 25:417–434
Okamura H (2003) Interleukin-18 [IL-1F4]. In: The cytokine handbook. Elsevier, Amsterdam
Gaggero A, De Ambrosis A, Mezzanzanica D et al (2004) A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and-4 processing. Oncogene 23:7552–7560
Escobar-Morreale HF, Villuendas G, Botella-Carretero JI et al (2003) Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 46:625–633
Gutman G, Soussan-Gutman L, Malcov M et al (2004) Interleukin-18 is high in the serum of IVF pregnancies with ovarian hyperstimulation syndrome. Am J Reprod Immunol 51:381–384
Lédée-Bataille N, Bonnet-Chea K, Hosny G et al (2005) Role of the endometrial tripod interleukin-18, -15, and -12 in inadequate uterine receptivity in patients with a history of repeated in vitro fertilization–embryo transfer failure. Fertil Steril 83:598–605. https://doi.org/10.1016/j.fertnstert.2004.11.021
Sugama S, Wirz SA, Barr AM et al (2004) Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine treatment. Neuroscience 128:451–458
Blankenberg S, Tiret L, Bickel C et al (2002) Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 106:24–30
Esposito K, Pontillo A, Ciotola M et al (2002) Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab 87:3864–3866. https://doi.org/10.1210/jcem.87.8.8781
Sugama S, Wang N, Shimokawa N et al (2006) The adrenal gland is a source of stress-induced circulating IL-18. J Neuroimmunol 172:59–65
Long X, Li R, Yang Y, Qiao J (2017) Overexpression of IL-18 in the proliferative phase endometrium of patients with polycystic ovary syndrome. Reprod Sci 24:252–257. https://doi.org/10.1177/1933719116653681
Dawood A, Alkafrawy N, Saleh S et al (2018) The relationship between IL-18 and atherosclerotic cardiovascular risk in Egyptian lean women with polycystic ovary syndrome. Gynecol Endocrinol 34:294–297
Sathyapalan T, Atkin SL (2010) Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators Inflamm. https://doi.org/10.1155/2010/758656
Yang Y, Qiao J, Li R, Li M-Z (2011) Is interleukin-18 associated with polycystic ovary syndrome? Reprod Biol Endocrinol 9:7
Kaya C, Pabuccu R, Berker B, Satiroglu H (2009) Plasma interleukin-18 levels are increased in the polycystic ovary syndrome: relationship of carotid intima-media wall thickness and cardiovascular risk factors. Fertil Steril 93:1200–1207. https://doi.org/10.1016/j.fertnstert.2008.10.070
Schmitz J, Owyang A, Oldham E et al (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479–490
Baekkevold ES, Roussigné M, Yamanaka T et al (2003) Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 163:69–79. https://doi.org/10.1016/S0002-9440(10)63631-0
Oboki K, Ohno T, Kajiwara N et al (2010) IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci 107:18581–18586
Bonilla WV, Fröhlich A, Senn K et al (2012) The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses. Science 335:984–989
Carlock CI, Wu J, Zhou C et al (2020) Unique temporal and spatial expression patterns of IL-33 in ovaries during ovulation and estrous cycle are associated with ovarian tissue homeostasis. J Immunol. https://doi.org/10.4049/jimmunol.1400381
Wu J, Carlock C, Zhou C et al (2015) IL-33 Is Required for disposal of unnecessary cells during ovarian atresia through regulation of autophagy and macrophage migration. J Immunol 194:2140–2147. https://doi.org/10.4049/jimmunol.1402503
Santulli P, Borghese B, Chouzenoux S et al (2012) Serum and peritoneal interleukin-33 levels are elevated in deeply infiltrating endometriosis. Hum Reprod 27:2001–2009. https://doi.org/10.1093/humrep/des154
Granne I, Southcombe JH, Snider JV et al (2011) ST2 and IL-33 in pregnancy and pre-eclampsia. PLoS ONE 6:e24463
Al-Taie WF, Al-Ruaei ZM, Hassan AJ (2014) Interleukin-33, oxidaive stres in prediabetic polycystic ovary syndrome patients with insulin resistance. J Fac Med Baghadad 56:113–117
Miller AM (2011) Role of IL-33 in inflammation and disease. J Inflamm 8:22
Karakose M, Demircan K, Tutal E et al (2016) Clinical significance of ADAMTS1, ADAMTS5, ADAMTS9 aggrecanases and IL-17A, IL-23, IL-33 cytokines in polycystic ovary syndrome. J Endocrinol Invest 39:1269–1275. https://doi.org/10.1007/s40618-016-0472-2
Demyanets S, Tentzeris I, Jarai R et al (2014) An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis. Cytokine 67:65–70
Zhang H-F, Xie S-L, Chen Y-X et al (2012) Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress. J Transl Med 10:120
Duleba AJ, Dokras A (2012) Is PCOS an inflammatory process? Fertil Steril 97:7–12
Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ (2004) C-reactive protein and the risk of incident colorectal cancer. JAMA 291:585–590
Lin EY, Nguyen AV, Russell RG, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193:727–740
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867
Jonjić N, Peri G, Bernasconi S et al (1992) Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells. J Exp Med 176:1165–1174
O’Byrne KJ, Dalgleish AG (2001) Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 85:473–483
Philip M, Rowley DA, Schreiber H (2004) Inflammation as a tumor promoter in cancer induction. Seminars in cancer biology. Elsevier, Amsterdam, pp 433–439
Pikarsky E, Porat RM, Stein I et al (2004) NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461–466
McSorley MA, Alberg AJ, Allen DS et al (2007) C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 109:933–941
Avall EL, Nordstroem L, Sjövall K, Eneroth P (1989) Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies. Eur J Gynaecol Oncol 10:395–405
Hefler LA, Concin N, Hofstetter G et al (2008) Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin cancer Res 14:710–714
Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM et al (2013) Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer. Eur Cytokine Netw 24:106–113
Kelly CCJ, Lyall H, Petrie JR et al (2001) Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86:2453–2455
Engin-Üstün Y, Üstün Y, Meydanli MM et al (2006) Are polycystic ovaries associated with cardiovascular disease risk as polycystic ovary syndrome? Gynecol Endocrinol 22:324–328
Cakal E, Ustun Y, Engin-Ustun Y et al (2011) Serum vaspin and C-reactive protein levels in women with polycystic ovaries and polycystic ovary syndrome. Gynecol Endocrinol 27:491–495
Lakhani K, Prelevic GM, Seifalian AM et al (2004) Polycystic ovary syndrome, diabetes and cardiovascular disease: risks and risk factors. J Obstet Gynaecol 24:613–621
Festa A, D’Agostino R Jr, Howard G et al (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42–47
Engeli S, Feldpausch M, Gorzelniak K et al (2003) Association between adiponectin and mediators of inflammation in obese women. Diabetes 52:942–947
Elci E, Kaya C, Cim N et al (2017) Evaluation of cardiac risk marker levels in obese and non-obese patients with polycystic ovaries. Gynecol Endocrinol 33:43–47. https://doi.org/10.1080/09513590.2016.1203893
Escobar-Morreale HF, Luque-Ramírez M, González F (2011) Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril 95:1048-1058.e2. https://doi.org/10.1016/j.fertnstert.2010.11.036
Fathi FH (2018) C-reactive protein and adiposity in women with polycystic ovary syndrome. Tikrit J Pure Sci 23:47–51
Neelaveni K, Menon R, Sahay R, Chandhrasekara Reddy G (2016) CRP levels and endothelial function in young women with PCOS. J Evol Med Dent Sci 5:5783–5786. https://doi.org/10.14260/jemds/2016/1305
Conway G, Dewailly D, Diamanti-Kandarakis E et al (2014) The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol 171:P1–P29
Radosh L (2009) Drug treatments for polycystic ovary syndrome. Am Fam Physician 79:671–676
PrabhuValsala YDGA (2020) γ-Linolenic acid ameliorates DHEA induced pro-inflammatory response in polycystic ovary syndrome via PPAR-γ signaling in rats. Reprod Biol 20:348–356. https://doi.org/10.1016/j.repbio.2020.05.004
Pawelczak M, Rosenthal J, Milla S et al (2014) Evaluation of the pro-inflammatory cytokine tumor necrosis factor-α in adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 27:356–359. https://doi.org/10.1016/j.jpag.2014.01.104
Xiong Y, Liang X, Yang X et al (2011) Low-grade chronic inflammation in the peripheral blood and ovaries of women with polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol 159:148–150
Oróstica L, Astorga I, Plaza-Parrochia F et al (2016) Proinflammatory environment and role of TNF-α in endometrial function of obese women having polycystic ovarian syndrome. Int J Obes 40:1715–1722. https://doi.org/10.1038/ijo.2016.154
Peng Z, Sun Y, Lv X et al (2016) Interleukin-6 levels in women with polycystic ovary syndrome: a systematic review and meta-analysis. PLoS ONE 11:1–14. https://doi.org/10.1371/journal.pone.0148531
Ghowsi M, Khazali H, Sisakhtnezhad S (2018) Evaluation of Tnf-α and Il-6 mRNAs expressions in visceral and subcutaneous adipose tissues of polycystic ovarian rats and effects of resveratrol. Iran J Basic Med Sci 21:165–174. https://doi.org/10.22038/ijbms.2017.24801.6167
Adams J, Liu Z, Ren YA et al (2016) Enhanced inflammatory transcriptome in the granulosa cells of women with polycystic ovarian syndrome. J Clin Endocrinol Metab 101:3459–3468. https://doi.org/10.1210/jc.2015-4275
Ravishankar Ram M, Sundararaman PG, Mahadevan S, Malathi R (2005) Cytokines and leptin correlation in patients with polycystic ovary syndrome: biochemical evaluation in south Indian population. Reprod Med Biol 4:247–254
Xue J, Li X, Liu P et al (2019) Inulin and metformin ameliorate polycystic ovary syndrome via anti-inflammation and modulating gut microbiota in mice. Endocr J 66:859–870. https://doi.org/10.1507/endocrj.EJ18-0567
Zhang T, Tian F, Huo R et al (2017) Detection of dendritic cells and related cytokines in follicular fluid of patients with polycystic ovary syndrome. Am J Reprod Immunol 78:1–6. https://doi.org/10.1111/aji.12717
Artimani T, Karimi J, Mehdizadeh M et al (2018) Evaluation of pro-oxidant-antioxidant balance (PAB) and its association with inflammatory cytokines in polycystic ovary syndrome (PCOS). Gynecol Endocrinol 34:148–152. https://doi.org/10.1080/09513590.2017.1371691
Escobar-Morreale HF, Botella-Carretero JI, Villuendas G et al (2004) Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab 89:806–811. https://doi.org/10.1210/jc.2003-031365
Zhang H, Wang X, Xu J et al (2020) IL-18 and IL-18 binding protein concentration in ovarian follicular fluid of women with unexplained infertility to PCOS during in vitro fertilization. J Reprod Immunol 138:103083
Weiping L, Qingfeng C, Shikun M et al (2006) Elevated serum RBP4 is associated with insulin resistance in women with polycystic ovary syndrome. Endocrine 30:283–287. https://doi.org/10.1007/s12020-006-0006-3
Ruan X, Dai Y (2009) Study on chronic low-grade inflammation and influential factors of polycystic ovary syndrome. Med Princ Pract 18:118–122. https://doi.org/10.1159/000189809
Bannigida DM, Nayak BS, Vijayaraghavan R (2020) Insulin resistance and oxidative marker in women with PCOS. Arch Physiol Biochem 126:183–186. https://doi.org/10.1080/13813455.2018.1499120
Benson S, Janssen OE, Hahn S et al (2008) Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome. Brain Behav Immun 22:177–184. https://doi.org/10.1016/j.bbi.2007.07.003
Bednarska S, Siejka A (2017) The pathogenesis and treatment of polycystic ovary syndrome: what’s new. Adv Clin Exp Med 26:359–367
Acknowledgements
The authors thank Vellore Institute of Technology, Vellore for their valuable support.
Funding
This work was supported by the “VIT SEED GRANT” and ICMRNational Task Force Project [F.No. 5/7/482/2010-RBMH&CH].
Author information
Authors and Affiliations
Contributions
VGA contributed to project development, planning, data management and manuscript editing. YDP participated in project development, data analysis and checking and manuscript editing. SAG participated in data collection and manuscript writing. All authors have read and approved the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Abraham Gnanadass, S., Divakar Prabhu, Y. & Valsala Gopalakrishnan, A. Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update. Arch Gynecol Obstet 303, 631–643 (2021). https://doi.org/10.1007/s00404-020-05951-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-020-05951-2